Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Gastroenterology  |  Oncology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location from dropdown

Colon cancer; rectal cancer Clinical Trials

A listing of Colon cancer; rectal cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.


Found (575) clinical trials

Blood and Stool Sample Collection in Subjects Participating in Colorectal Cancer Screening: Act Bold

Subjects will be men and women, 40 years of age or older who are scheduled for a colonoscopy. Approximately 3,000 subjects will be enrolled.

Phase N/A

A Study to Compare the Efficacy of Arfolitixorin Versus Leucovorin in Combination With 5 Fluorouracil Oxaliplatin and Bevacizumab in Patients With Advanced Colorectal Cancer

This is a multicenter, randomized, parallel-group, Phase III study in at least 440 patients with advanced colorectal cancer to compare the efficacy of treatment with arfolitixorin versus Leucovorin in combination with 5-fluorouracil, oxaliplatin, and bevacizumab according to modified FOLFOX-6 until PD according to RECIST 1.1 criteria.


Colorectal Metastasis Prevention International Trial 2

The short perioperative period (days to weeks around surgery) is characterized by stress-inflammatory responses, including catecholamines (CAs, e.g., adrenaline) and prostaglandins (PGs, e.g., prostaglandin-E2) release, and induce deleterious pro-metastatic effects. Animal studies implicated excess perioperative release of CAs and PGs in facilitating cancer progression by affecting the malignant tissue, its ...


Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal Tumors

This is a single-arm phase II study of twenty-one subjects with mucinous adenocarcinoma of the colon, rectum, or appendix with prior systemic therapy with a fluoropyrimidine, oxaliplatin, and irinotecan. Treatment will consist of nivolumab 480mg every 4 weeks and ipilimumab 1mg/kg every 8 weeks until disease progression, unacceptable toxicity, or ...


9-ING-41 in Patients With Advanced Cancers

9-ING-41 is a first-in-class, intravenously administered, maleimide-based small molecule potent selective GSK-3 inhibitor with significant pre-clinical antitumor activity. GSK-3 is a serine/threonine kinase initially described as a key regulator of metabolism and has a role in diverse disease processes including cancer, immune disorders, pathologic fibrosis, metabolic disorders, and neurological disorders. ...


Prognostic Biomarker for CRC

This is a prospective observational study. Tumor tissue specimens and surgical specimens are obtained from the Sixth Affiliated Hospital, Sun Yat-sen University. The samples are analyzed for biomarkers. The biomarkers are correlated with clinical outcomes (failure-free survival, overall survival, tumor response to treatment (e.g. tumor regression grade for rectal cancer), ...

Phase N/A

Mebendazole as Adjuvant Treatment for Colon Cancer

mebendazole as adjuvant treatment for colon cancer


Measurement of Perioperative Glomerular Filtration Rate

The considerable morbidity and mortality associated with perioperative acute kidney injury (AKI) is well documented and known to complicate recovery from surgery. Accurate, direct measurements of glomerular filtration rate (GFR) may provide a tool to monitor perioperative onset of rapidly changing renal function. This may subsequently lead to design of ...

Phase N/A

Peptide-based Immunization for Colon- and and Pancreas-carcinoma (PICOP GLOBAL)

Colorectal and pancreatic cancers are among the most common causes of cancer-related death over the world. Patient-individualized treatments and enhancement of the immune response via vaccination are among new therapeutic options. The aim of this study is to identify tumor molecular particularities and neoepitopes among patients with colorectal and pancreatic ...

Phase N/A

Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening

Colorectal cancer (CRC) is the 2nd leading cause of cancer death in the US, though CRC death can be reduced by screening. In the NCI-funded UT Southwestern-Parkland PROSPR Center (U54 CA163308), mailed FIT-based outreach doubled the proportion of patients up-to-date with screening compared to usual care. Investigators are now conducting ...

Phase N/A